Outcome of intravenous thrombolysis in stroke patients weighing over 100 kg

Cerebrovascular Diseases

Volumn 32, Issue 3, 2011, Pages 201-206

  Sarikaya, H ^a   Arnold, M ^b   Engelter, S T ^c   Lyrer, P A ^c   Mattle, H P ^b   Michel, P ^d   Odier, C ^d   Weder, B ^e   Siebel, P ^e   Mueller, F ^f   Ballinari, P ^g   Georgiadis, D ^a   Baumgartner, R W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Kantonsspital Muensterlingen   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Clinical outcome; Ischemic stroke; Overweight; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; BODY WEIGHT; BRAIN HEMORRHAGE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANKIN SCALE; SEX DIFFERENCE; STROKE; SYMPTOMATIC INTRACRANIAL HEMORRHAGE; TREATMENT OUTCOME;

AGED; BODY WEIGHT; CHI-SQUARE DISTRIBUTION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; ODDS RATIO; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SWITZERLAND; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79961124146     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000328813     Document Type: Article

References (30)

1. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
2. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF: Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-1711. (Pubitemid 46691097)
3. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, et al: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640.
4. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, Torner JC, Marler JR: Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645.
5. Obesity and overweight. World Health Organization web site. September 2006.
6. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH: Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke 2006; 37: 1060-1064.
7. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssonen K, Salonen JT: Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37: 806-811. (Pubitemid 43731913)
8. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, Tofler GH: Association between obesity and a prothrombotic state: The Framingham Offspring Study. Thromb Haemost 2004; 91: 683-689. (Pubitemid 38477447)
9. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J: Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004; 91: 1146-1151. (Pubitemid 38821271)
10. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J: Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994; 25: 2220-2226. (Pubitemid 24338379)
11. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, Muller F, Luthy R, Arnold M, Michel P, Mattle HP, Tettenborn B, Hungerbuhler HJ, Baumgartner RW, Sztajzel R, Bogousslavsky J, Lyrer PA: Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005; 65: 1795-1798.
12. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41. (Pubitemid 23014379)
13. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
14. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
15. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251. (Pubitemid 28470336)
16. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Davalos A, Erila T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kohrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G: Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 2008; 39: 3316-3322.
17. Lou M, Selim M: Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients? Cerebrovasc Dis 2009; 27: 84-90.
18. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D: Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. Circulation 1989; 80: 1222-1230. (Pubitemid 19282510)
19. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
20. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329: 1615-1622.
21. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R: Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
22. Towfighi A, Ovbiagele B: The impact of body mass index on mortality after stroke. Stroke 2009; 40: 2704-2708.
23. Zhou M, Offer A, Yang G, Smith M, Hui G, Whitlock G, Collins R, Huang Z, Peto R, Chen Z: Body mass index, blood pressure, and mortality from stroke: A nationally representative prospective study of 212,000 Chinese men. Stroke 2008; 39: 753-759. (Pubitemid 351619555)
24. Arnlov J, Ingelsson E, Sundstrom J, Lind L: Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236.
25. Stein PD, Beemath A, Olson RE: Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-980. (Pubitemid 41297761)
26. Cohen A: Pharmacokinetics of the recombinant thrombolytic agents: What is the clinical significance of their different pharmacokinetic parameters? BioDrugs 1999; 11: 115-123. (Pubitemid 29128323)
27. Eppler S, Senn T, Gilkerson E, Modi NB: Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: A comparison of three dosing regimens. Biopharm Drug Dispos 1998; 19: 31-38. (Pubitemid 28064489)
28. Tanswell P, Seifried E, Stang E, Krause J: Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator. Arzneimittelforschung 1991; 41: 1310-1319.
29. Menon S, Kelly AM: How accurate is weight estimation in the emergency department? Emerg Med Australas 2005; 17: 113-116. (Pubitemid 40592399)
30. Rimm EB, Stampfer MJ, Colditz GA, Giovannucci E, Willett WC: Effectiveness of various mailing strategies among nonrespondents in a prospective cohort study. Am J Epidemiol 1990; 131: 1068-1071. (Pubitemid 20178628)